Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...
Potential to be the first targeted therapy for GBS: Successful pivotal Phase 3 trial showed ANX005 helped patients get better sooner with rapid improvement in muscle strength and more complete ...
A free tablet from the government can support your education, entertainment, and digital needs. In 2025, both government programs and partners can help you get one. You can apply for government ...
No matter what you're looking for, there's a tablet that can do it. We've found some dramatic price drops to start the year off, and here are five of the best tablet deals for January. For an ...